1.Ndubaku, C.O.,Heffron, T.P.,Staben, S.T., et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J.Med.Chem. 56(11), 4597-45610 (2013).
2.Lopez, S.,Schwab, C.L.,Cocco, E., et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol.Oncol. 135(2), 312-317 (2014).
3.Zumsteg, Z.S.,Morse, S.,Krigsfeld, G., et al. Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations. Clin.Cancer.Res 22(8), 2009-2019 (2016).
|
